Day: September 14, 2025

VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the Company to commercialize RECELL GO in Europe and in other markets that recognize the CE Mark. “CE Mark for RECELL® GO is an important milestone for AVITA Medical and for patients,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “It enables us to bring this option to burn centers and clinicians in Europe to support their treatment of patients with acute wound injuries.” RECELL GO is a point-of-care device used by healthcare professionals to prepare a suspension of a patient’s own skin cells (Spray-On Skin™...

SHANGHAI, Sept. 14, 2025 (GLOBE NEWSWIRE) — At its 10th H2H Healthcare Ecosystem Conference, Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced the release of its proprietary “XingShi” Large Language Model (“XS LLM”), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians’ available time. XS LLM integrates multimodal capabilities — image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning — while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: “AI Knowledge Agent”, “AI Guidance Agent”, “AI...

WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The poster and oral presentations will be delivered by Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan. Monopar’s poster presentation is available at the following link: https://www.monopartx.com/ALXN1840-ANA-2025-Poster-14-Sep-2025. The...

Luxembourg – 14 September 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a major1 project under the long-term agreement (LTA) with Aramco that relates to certain facilities located offshore Saudi Arabia. The contract scope includes the engineering, procurement, construction, and installation (EPCI) of 106 kilometres of infield and export pipelines, modification to existing topsides, and associated hook-up activities. Project management and engineering work will begin immediately at Subsea7’s offices in Saudi Arabia and the UAE. Offshore activities are scheduled for 2027 and 2028. David Bertin, Senior Vice President for Subsea7 Global Projects Centre East, said: “This project marks another important milestone and reinforces our long-term strategic engagement with Aramco. We look forward to working...